Menu
← Oncology Approval Tracker
FDA DECISION ·
Xpovio
selinexor · Karyopharm Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including disease arising from follicular lymphoma, after at least two systemic therapy lines.
LAMPGEN ANALYSIS
Why it matters
Added oral nuclear export inhibition for a heavily pretreated lymphoma population under accelerated approval.
What research teams should watch
Confirm histology and prior lines and schedule monitoring for cytopenias and electrolyte changes.
PRIMARY RECORDS